This review discusses the evidence in support of the use of alectinib, its pharmacology including its mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Benjamin Solomon, a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne.
Please login below to download this issue (PDF)